Fortune 500 rank: 444
2008 revenue: $5.3 billion
2008 total shareholder return: 11.1%
The No. 2 biotech on the Fortune 500 (after Amgen), Gilead is known for its top-selling HIV drugs, particularly the first single-pill HIV treatment. Its 11% gain in 2008 caps an impressive 5-year run - a return of more than 200%.
NEXT: General Mills